Cancers, Vol. 12, Pages 53: MDA-9/Syntenin (SDCBP) Is a Critical Regulator of Chemoresistance, Survival and Stemness in Prostate Cancer Stem Cells
Cancers, Vol. 12, Pages 53: MDA-9/Syntenin (SDCBP) Is a Critical Regulator of Chemoresistance, Survival and Stemness in Prostate Cancer Stem Cells
Cancers doi: 10.3390/cancers12010053
Authors:
Sarmistha Talukdar
Swadesh K. Das
Anjan K. Pradhan
Luni Emdad
Jolene J. Windle
Devanand Sarkar
Paul B. Fisher
Despite some progress, treating advanced prostate cancer remains a major clinical challenge. Recent studies have shown that prostate cancer can originate from undifferentiated, rare, stem cell-like populations within the heterogeneous tumor mass, which play seminal roles in tumor formation, maintenance of tumor homeostasis and initiation of metastases. These cells possess enhanced propensity toward chemoresistance and may serve as a prognostic factor for prostate cancer recurrence. Despite extensive studies, selective targeted therapies against these stem cell-like populations are limited and more detailed experiments are required to develop novel targeted therapeutics. We now show that MDA-9/Syntenin/SDCBP (MDA-9) is a critical regulator of survival, stemness and chemoresistance in prostate cancer stem cells (PCSCs). MDA-9 regulates the expression of multiple stem-regulatory genes and loss of MDA-9 causes a complete collapse of the stem-regulatory network in PCSCs. Loss of MDA-9 also sensitizes PCSCs to multiple chemotherapeutics with different modes of action, such as docetaxel and trichostatin-A, suggesting that MDA-9 may regulate multiple drug resistance....
Source: Cancers - Category: Cancer & Oncology Authors: Sarmistha Talukdar Swadesh K. Das Anjan K. Pradhan Luni Emdad Jolene J. Windle Devanand Sarkar Paul B. Fisher Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Docetaxel | Genetics | Prostate Cancer | Stem Cell Therapy | Stem Cells | Study | Taxotere | Undifferentiated Carcinoma